NEWS | BEAM Alliance

NEWS

Da Volterra Announces Enrollment of First Patients in SHIELD, a Phase 2 Clinical Trial with DAV132, a Novel Microbiota Protective Therapy

Paris (France), 20 December, 2018 – Da Volterra, a clinical-stage microbiome company focused on developing new therapeutics to protect the intestinal microbiota, announced today that it has enrolled the first patients in a Phase 2 trial called SHIELD, evaluating its innovative product DAV132 in patients at high risk of Clostridium difficile Infection (CDI). DAV132 is Da Volterra’s most advanced product designed to preserve the intestinal microbiota and to prevent life-threatening conditions such as CDI due to antibiotic treatments.

Full PR available here